UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a report issued on Tuesday,Benzinga reports. HC Wainwright currently has a $64.00 price target on the stock.

Several other brokerages also recently weighed in on URGN. LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price objective on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of UroGen Pharma in a report on Tuesday, February 18th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $40.00.

UroGen Pharma Stock Performance

NASDAQ:URGN opened at $9.51 on Tuesday. The company has a market cap of $223.05 million, a P/E ratio of -3.02 and a beta of 1.08. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The firm’s 50 day moving average is $10.64 and its two-hundred day moving average is $12.05. UroGen Pharma has a fifty-two week low of $9.29 and a fifty-two week high of $20.70.

Insider Activity at UroGen Pharma

In related news, insider Mark Schoenberg sold 4,551 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the transaction, the insider now directly owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the sale, the general counsel now owns 26,468 shares of the company’s stock, valued at $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by insiders.

Institutional Trading of UroGen Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of URGN. KLP Kapitalforvaltning AS bought a new stake in UroGen Pharma during the fourth quarter worth about $59,000. Lazard Asset Management LLC purchased a new stake in shares of UroGen Pharma in the 4th quarter worth approximately $67,000. Aquatic Capital Management LLC purchased a new stake in shares of UroGen Pharma in the 4th quarter worth approximately $101,000. China Universal Asset Management Co. Ltd. increased its position in UroGen Pharma by 90.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after buying an additional 3,856 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in UroGen Pharma by 221.8% in the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after acquiring an additional 5,890 shares in the last quarter. Institutional investors own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.